[go: up one dir, main page]

AU2001230026A1 - 2,4-diaminothiazole derivatives - Google Patents

2,4-diaminothiazole derivatives

Info

Publication number
AU2001230026A1
AU2001230026A1 AU2001230026A AU3002601A AU2001230026A1 AU 2001230026 A1 AU2001230026 A1 AU 2001230026A1 AU 2001230026 A AU2001230026 A AU 2001230026A AU 3002601 A AU3002601 A AU 3002601A AU 2001230026 A1 AU2001230026 A1 AU 2001230026A1
Authority
AU
Australia
Prior art keywords
diaminothiazole
derivatives
diaminothiazole derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001230026A
Inventor
Andrew Neil Bowler
Bo Falck Hansen
Peter Kurtzhals
Preben Houlberg Olesen
Anders Robert Sorensen
Helle Worsaae
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of AU2001230026A1 publication Critical patent/AU2001230026A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2001230026A 2000-02-04 2001-02-01 2,4-diaminothiazole derivatives Abandoned AU2001230026A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200000187 2000-02-04
DKPA200000187 2000-02-04
PCT/DK2001/000073 WO2001056567A1 (en) 2000-02-04 2001-02-01 2,4-diaminothiazole derivatives and their use as glycogen synthase kinase-3 (gsk-3) inhibitors

Publications (1)

Publication Number Publication Date
AU2001230026A1 true AU2001230026A1 (en) 2001-08-14

Family

ID=8159085

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001230026A Abandoned AU2001230026A1 (en) 2000-02-04 2001-02-01 2,4-diaminothiazole derivatives

Country Status (2)

Country Link
AU (1) AU2001230026A1 (en)
WO (1) WO2001056567A1 (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
ID30460A (en) 1999-04-15 2001-12-06 Bristol Myers Squibb Co INHIBITORS, INHIBITORS, THYROCIN CINASE PROTEIN
US20070208087A1 (en) 2001-11-02 2007-09-06 Sanders Virginia J Compounds, compositions and methods for the treatment of inflammatory diseases
US6756374B2 (en) 2001-01-22 2004-06-29 Hoffmann-La Roche Inc. Diaminothiazoles having antiproliferative activity
AU2002346053B2 (en) * 2001-06-22 2008-03-13 Merck & Co., Inc. Tyrosine kinase inhibitors
EP1417188A1 (en) * 2001-08-03 2004-05-12 Novo Nordisk A/S Novel 2,4-diaminothiazole derivatives
TWI335221B (en) * 2001-09-27 2011-01-01 Alcon Inc Inhibtors of glycogen synthase kinase-3 (gsk-3) for treating glaucoma
IL162838A0 (en) 2002-01-04 2005-11-20 Univ Rockefeller Compositions and methods for prevention and treatment peptide-of amyloid- related disorders
SE0201194D0 (en) * 2002-04-19 2002-04-19 Astrazeneca Ab New compounds
PT1511710E (en) 2002-05-31 2014-02-26 Proteotech Inc Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer s disease, type 2 diabetes, and parkinson s disease
US6872724B2 (en) 2002-07-24 2005-03-29 Merck & Co., Inc. Polymorphs with tyrosine kinase activity
WO2004014904A1 (en) * 2002-08-09 2004-02-19 Pfizer Inc. Antiproliferative 2-(heteroaryl)-aminothiazole compounds, pharmaceutical compositions and methods for their use
AU2004251668B2 (en) 2003-06-03 2008-03-20 Triad Therapeutics, Inc 5-membered heterocycle-based p-38 inhibitors
PL2298743T3 (en) 2003-06-26 2013-02-28 Novartis Ag 5-membered heterocycle-based P38 kinase inhibitors
US20070167329A1 (en) * 2003-12-24 2007-07-19 Bayer Cropscience Gmbh Plant growth regulation
EP1732905A1 (en) 2004-03-31 2006-12-20 Lexicon Genetics Incorporated 2-aminomethylthiazole-5-carboxamides as protein kinase modulators
US7211576B2 (en) 2004-04-20 2007-05-01 Hoffmann-La Roche Inc. Diaminothiazoles
JPWO2006008874A1 (en) * 2004-05-21 2008-05-01 萬有製薬株式会社 Cdk4, 6 selective inhibitor having aminothiazole skeleton
US7423053B2 (en) 2004-07-15 2008-09-09 Hoffmann-La Roche Inc. 4-Aminothiazole derivatives
EP2275095A3 (en) 2005-08-26 2011-08-17 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
CA2625153A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP1849785A1 (en) * 2006-04-28 2007-10-31 Neuropharma, S.A. N-(2-Thiazolyl)-amide derivatives as GSK-3 inhibitors
JP2009536669A (en) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド Neurogenesis by angiotensin regulation
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
EP2076288A2 (en) * 2006-09-22 2009-07-08 Braincells, Inc. Combination comprising an hmg-coa reductase inhibitor and a second neurogenic agent for treating a nervous system disorder and increasing neurogenesis
WO2008080134A2 (en) * 2006-12-22 2008-07-03 Rigel Pharmaceuticals, Inc. 4-amin0-2- (hetero) arylamino-5- (hetero) arylthiazoles useful as axl inhibitors
JP2010518014A (en) * 2007-01-31 2010-05-27 バーテックス ファーマシューティカルズ インコーポレイテッド 2-Aminopyridine derivatives useful as kinase inhibitors
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
JP6166534B2 (en) 2009-08-05 2017-07-19 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． Novel regulatory proteins and inhibitors
CN103141486B (en) * 2013-04-01 2014-05-28 湖南大学 Application of 4-(benzofuran-5-yl)-2-phenzyl aminothiazole as bactericide
WO2018089902A1 (en) * 2016-11-13 2018-05-17 Apogee Biotechnology Corporation Diaminothiazole compounds, compositions and methods of use
WO2020163812A1 (en) 2019-02-08 2020-08-13 Frequency Therapeutics, Inc. Valproic acid compounds and wnt agonists for treating ear disorders
CN120093741A (en) * 2020-04-24 2025-06-06 拜耳公司 Substituted aminothiazoles as DGKZETA inhibitors for immune activation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3804531A1 (en) * 1988-02-13 1989-08-24 Bayer Ag 5-CYANO-2,4-DIAMINO-THIAZOLE DERIVATIVES
TW513418B (en) * 1996-07-31 2002-12-11 Otsuka Pharma Co Ltd Thiazole derivatives, their production and use
CN1158269C (en) * 1997-10-27 2004-07-21 阿古龙制药公司 4-aminothiazole derivs, their preparation and their use as inhibitors of cyclin-dependent kinases
US6040321A (en) * 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
EP1087951B9 (en) * 1998-06-18 2006-09-13 Bristol-Myers Squibb Company Carbon substituted aminothiazole inhibitors of cyclin dependent kinases
CN1312807A (en) * 1998-06-19 2001-09-12 希龙公司 Inhibitors of glycogen synthase kinase 3

Also Published As

Publication number Publication date
WO2001056567A1 (en) 2001-08-09
WO2001056567A8 (en) 2001-11-08

Similar Documents

Publication Publication Date Title
AU2001230026A1 (en) 2,4-diaminothiazole derivatives
AU2001280099A1 (en) 4-acylaminopyrazole derivatives
AU2001230584A1 (en) 1h-imidazopyridine derivatives
AU2002361992A1 (en) 1,4-dihydro-1,4-diphenylpyridine derivatives
AU2001230537A1 (en) Pyridoxazine derivatives
AU2001281802A1 (en) 6-phenylpyrrolopyrimidinedione derivatives
AU2001278790A1 (en) 1h-imidazopyridine derivatives
AU2002213978A1 (en) Substituted C-cyclohexylmethylamine derivatives
AU2002212301A1 (en) Diazacycloalkanedione derivatives
AU3819200A (en) 2,4-diamino-pyrimidine derivatives
AU5256301A (en) Froindazole derivative
AU2002212959A1 (en) Cycloalkylfluorosulfonamide derivatives
AU2001254661A1 (en) Aminosulfonylbiphenyl derivatives
AU2002215212A1 (en) 1-methylcarbapenem derivatives
ZA200206151B (en) Substituted amionomethyl-phenyl-cyclohexane derivatives.
AU2001254731A1 (en) Substituted phenyluracils
AU2001230565A1 (en) Perfluoroisopropylbenzene derivatives
AU2001289937A1 (en) Substituted 1-aminobutan-3-ol derivatives
AU6594401A (en) 6-heterocyclyl-3-oxo-3,4-dihydro-quinoxalines
MXPA03002737A (en) Substituted 1-aminobutan-3-ol derivatives.
AU2001234313A1 (en) Novel phenylheteroalkylamine derivatives
AU2001242772A1 (en) 3-substituted-4-pyrimidone derivatives
ZA200206150B (en) Aminomethyl-phenyl-cyclohexanone derivatives.
AU2002218400A1 (en) 3-substituted 2,7-naphthyridin-1-yl derivatives
AU2001293697A1 (en) N-substituted-1-amino-1,1-dialkylcarboxylic acid derivatives